Navigation Links
Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Date:5/8/2012

CAMBRIDGE, Mass., May 8, 2012 /PRNewswire/ -- Eutropics Pharmaceuticals today announced that the United States Patent and Trademark Office has issued patent number 8,168,755 entitled, "Antibodies specific to heterodimers of Bcl-2 family and uses thereof."

The patent provides a novel method for extending Eutropics' BH3 profiling technology, which is exclusively licensed from the Dana Farber Cancer Institute. This technology assesses the ability of a key part of the cancer cell to respond to chemotherapies. This understanding provides a powerful tool for physicians to know ahead of time if a particular cancer treatment will, or will not work in a given patient and can be used to guide the use of existing drugs. This new invention by Eutropics provides a method for extending utility of the technology within solid tumors.

Eutropics is currently involved in the commercialization of the BH3 profiling assay. The test is being developed for use in guiding treatments for multiple myeloma and acute myelogenous leukemia patients as well as solid cancers. This work is being done in collaboration with the Dana Farber Cancer Institute, UMass Worcester Medical School, MD Anderson Cancer Center, and the NCI/NIH.

Michael Cardone, Co-Founder and CEO of Eutropics commented, "We are very pleased with the progress being made toward the commercial development of BH3 profiling at Eutropics. Gaining protection on this new intellectual property will help extend the process into a broader range of oncology indications. The company has made excellent progress in our clinical studies and is working very hard to provide a tool to help physicians acquire this diagnostic test that will help guide the use of chemotherapies, ultimately leading to better patient outcomes."

Eutropics Pharmaceuticals was founded on research and technology that will enable delivery of personalized medicines to patients suffering from cancer. They seek to displace current treatment paradigms by guiding the use of novel therapies tailored to an individual's cancer profile identified by the proprietary BH3 profiling diagnostic technology. This personalized approach utilizing unique diagnostics and therapeutics should result in more effective treatments and reduce unnecessary suffering.


'/>"/>
SOURCE Eutropics Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
4. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
5. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today the ... KbioBox developed a sophisticated “3 click” gene dditing off target analysis program and ... website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, ...
(Date:12/8/2016)... Ames, Iowa (PRWEB) , ... December 08, 2016 , ... ... of asynchronous approvals for biotech crops. The authors focus on the economic effects in ... the global approval of new biotech crops and the resultant risk of low level ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
(Date:12/8/2016)... to fuel Philadelphia,s innovative digital ... Southeastern Pennsylvania (" Ben Franklin "); Independence ... Cross; and Safeguard Scientifics ("Safeguard") (NYSE: SFE ... funding initiative over a four year period to grow ... burgeoning economic vitality in digital health, Ben Franklin ...
Breaking Biology Technology:
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):